FIG. 1: Hair-transplantation - Harvesting with the follicular unit excision method (FUE) for HAIROID™️ replication at “patient zero”.
FIG. 2: In HAIROID ™️ it is possible to observe the dermal papilla, hair matrix, outer and inner root sheath and hair shaft [hematoxylin eosin staining].
Our first focus is to produce, autologous and allogeneic, hypoimmunogenic GENE EDITED hair-follicles for hair-loss treatment in clinics and transplantation into the human scalp.
With its patented high-tech 3D stem-cell merger technology, HAIROID ™️, which is a spin-off from an EUROPEAN CONTRACT RESEARCH ORGANISATION, performs its own development that is equivalent to pharmaceutical and cosmetics companies. This is done in the drug discovery and preclinical testing phase in order to increase their efficiency and the success rate of compounds that pass the clinical trials, i.e. enhanced relevance.
Here we focus on ALOPECIA diseases, the performance of highly sophisticated tissue (hair)-engineering and in silico computerial screening technologies.
Prior to the transplantation of bioengineered hair-follicles we will provide patients with cell viability/proliferation assays, DERMAL PAPILLAE isolation, HAIR BULGE STEM CELL isolation, IPSC reprogramming, tissue engineering and cryogenic storage.
For developers of STEM-CELL THERAPIES we will provide our patent protected hypoimmunogenic Dermal Papillae cells in order to contribute to the development of STEM-CELL THERAPIES FOR ALOPECIA. THOSE METHODS CAN BE APPLIED TO ALREADY PRODUCED CELL LINES.
The approach requires intensive identification of pathogenic conditions and the precise identification of specific phenotypes.
Image 3.: HAIROID™️ prototype April 2018